Cannabinoid receptor type 1

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cannabinoid receptor 1 (brain)

Rendering of CNR1 from PDB 1LVQ
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols CNR1 ; CANN6; CB-R; CB1; CB1A; CB1K5; CB1R; CNR
External IDs OMIM114610 MGI104615 HomoloGene7273 IUPHAR: CB1 ChEMBL: 218 GeneCards: CNR1 Gene
RNA expression pattern
PBB GE CNR1 213436 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 1268 12801
Ensembl ENSG00000118432 ENSMUSG00000044288
UniProt P21554 P47746
RefSeq (mRNA) NM_001160226 NM_007726
RefSeq (protein) NP_001153698 NP_031752
Location (UCSC) Chr 6:
88.85 – 88.88 Mb
Chr 4:
33.92 – 33.95 Mb
PubMed search [1] [2]

The cannabinoid receptor type 1, often abbreviated as CB1, is a G protein-coupled cannabinoid receptor located primarily in the central and peripheral nervous system. It is activated by the endocannabinoid neurotransmitters anandamide and 2-arachidonoyl glyceride (2-AG); by plant cannabinoids, such as the compound THC, an active ingredient of the psychoactive drug cannabis; and by synthetic analogues of THC, such as dronabinol.

Structure[edit]

The CB1 receptor shares the structure characteristic of all G-protein-coupled receptors, possessing seven transmembrane domains connected by three extracellular and three intracellular loops, an extracellular N-terminal tail, and an intracellular C-terminal tail.[1] These receptors may exist as homodimers or form heterodimers or oligomers when coexpressed with one or more classes of G-protein-coupled receptors. Observed heterodimers include A2ACB1, A2A, CB1D2, orexin 1/CB1, while many more may only be stable enough to exist in vivo.[2] Recent evidence suggests that these receptors may also possess an allosteric binding site, which may become a target for enhancing the clinical modulatory effects of cannabinoids.[2]

Mechanism[edit]

The CB1 receptor is a pre-synaptic heteroreceptor that modulates neurotransmitter release when activated in a dose-dependent, stereoselective and pertussis toxin-sensitive manner.[3] The CB1 receptor is activated by cannabinoids, generated naturally inside the body (endocannabinoids ) or introduced into the body as cannabis or a related synthetic compound.

Research suggests that the majority of CB1 receptors are coupled through Gi/o proteins. Upon activation, CB1 receptor exhibits its effects mainly through activation of Gi, which decreases intracellular cAMP concentration by inhibiting its production enzyme, adenylate cyclase, and increases mitogen-activated protein kinase (MAP kinase) concentration. Alternatively, in some rare cases CB1 receptor activation may be coupled to Gs proteins, which stimulate adenylate cyclase.[2] cAMP is known to serve as a second messenger coupled to a variety of ion channels, including the positively influenced inwardly rectifying potassium channels (=Kir or IRK),[4] and calcium channels, which are activated by cAMP-dependent interaction with such molecules as protein kinase A (PKA), protein kinase C (PKC), Raf-1, ERK, JNK, p38, c-fos, c-jun, and others.[5] In terms of function, the inhibition of intracellular cAMP expression shortens the duration of pre-synaptic action potentials by prolonging the rectifying potassium A-type currents, which is normally inactivated upon phosphorylation by PKA. This inhibition grows more pronounced when considered with the effect of activated CB1 receptors to limit calcium entry into the cell, which does not occur through cAMP but by a direct G-protein-mediated inhibition. As presynaptic calcium entry is a requirement for vesicle release, this function will decrease the transmitter that enters the synapse upon release.[1] The relative contribution of each of these two inhibitory mechanisms depends on the variance of ion channel expression by cell type.

The CB1 receptor can also be modulated by allosterically synthetic ligands[6] in a positive[7] and negative[8] manner. In vivo exposure to THC impairs long-term potentiation and leads to a reduction of phosphorylated CREB.[9]

In summary, CB1 receptor activity has been found to be coupled to certain ion channels, in the following manner:[2]

  • Positively to inwardly rectifying and A-type outward potassium channels.
  • Negatively to D-type outward potassium channels
  • Negatively to N-type and P/Q-type calcium channels.

Expression[edit]

The CB1 receptor is encoded by the gene CNR1,[3] located on human chromosome 6.[1] Two transcript variants encoding different isoforms have been described for this gene.[3] CNR1 orthologs [10] have been identified in most mammals.

The CB1 receptor is expressed pre-synaptically at both glutaminergic and GABAergic interneurons and, in effect, acts as a neuromodulator to inhibit release of glutamate and GABA.[1] Repeated administration of receptor agonists may result in receptor internalization and/ or a reduction in receptor protein signalling.[2]

The inverse agonist MK-9470 makes it possible to produce in vivo images of the distribution of CB1 receptors in the human brain with positron emission tomography.[11]

Brain[edit]

Cnr1 is widely expressed in all major regions of the postnatal day 14 mouse brain, but is conspicuously absent in much of the thalamus. Allen Brain Atlases

CB1 receptors are expressed most densely in the central nervous system and are largely responsible for mediating the effects of cannabinoid binding in the brain. Endocannabinoids released by a depolarized neuron bind to CB1 receptors on either pre-synaptic glutamatergic or GABAergic neurons, resulting in a respective decrease in either glutamate or GABA release. Limiting glutamate release causes reduced excitation, while limiting GABA release suppresses inhibition, a common form of short-term plasticity in which the depolarization of a single neuron induces a reduction in GABA-mediated inhibition, in effect exciting the postsynaptic cell.[1]

Varying levels of CB1 expression can be detected in the olfactory bulb, cortical regions (neocortex, pyriform cortex, hippocampus, and amygdala), several parts of basal ganglia, thalamic and hypothalamic nuclei, and other subcortical regions (e.g., the septal region), cerebellar cortex, and brainstem nuclei (e.g., the periaqueductal gray).[5]

Hippocampal formation[edit]

CB1 mRNA transcripts are abundant in GABAergic interneurons of the hippocampus, indirectly reflecting the expression of these receptors and elucidating the established effect of cannabinoids on memory. These receptors are densely located in cornu ammonis pyramidal cells, which are known to release glutamate. Cannabinoids suppress the induction of LTP and LTD in the hippocampus by inhibiting these glutamatergic neurons. By reducing the concentration of glutamate released below the threshold necessary to depolarize the postynaptic receptor NMDA,[1] a receptor known to be directly related to the induction of LTP and LTD, cannabinoids are a crucial factor in the selectivity of memory. These receptors are highly expressed by GABAergic interneurons as well as glutamatergic principal neurons. However, a higher density is found within GABAergic cells.[12] The coexpression of CB1 This means that, although synaptic strength/frequency, and thus potential to induce LTP, is lowered, net hippocampal activity is raised. In addition, CB1 receptors in the hippocampus indirectly inhibit the release of acetylcholine. This serves as the modulatory axis opposing GABA, decreasing neurotransmitter release. An undetermined complex fractal-based, feedforward network allows the brain to weaken specific synapses while others are enhanced, allowing long-range structure to be formed. Cannabinoids also likely play an important role in the development of memory through their neonatal promotion of myelin formation, and thus the individual segregation of axons.

Basal ganglia[edit]

CB1 receptors are expressed throughout the basal ganglia and have well-established effects on movement in rodents. As in the hippocampus, these receptors inhibit the release of glutamate or GABA transmitter, resulting in decreased excitation or reduced inhibition based on the cell they are expressed in. Consistent with the variable expression of both excitatory glutamate and inhibitory GABA interneurons in both the basal ganglia's direct and indirect motor loops, synthetic cannabinoids are known to influence this system in a dose-dependent triphasic pattern. Decreased locomotor activity is seen at both higher and lower concentrations of applied cannabinoids, whereas an enhancement of movement may occur upon moderate dosages.[1] However, these dose-dependent effects have been studied predominately in rodents, and the physiological basis for this triphasic pattern warrants future research in humans. Effects may vary based on the site of cannabinoid application, input from higher cortical centers, and whether drug application is unilateral or bilateral.

Cerebellum and neocortex[edit]

The role of the CB1 receptor in the regulation of motor movements is complicated by the additional expression of this receptor in the cerebellum and neocortex, two regions associated with the coordination and initiation of movement. Research suggests that anadamide is synthesized by Purkinje cells and acts on presynaptic receptors to inhibit glutamate release from granule cells or GABA release from the terminals of basket cells. In the neocortex, these receptors are concentrated on local interneurons in cerebral layers II-III and V-VI.[1] Compared to rat brains, humans express more CB1 receptors in the cerebral cortex and amygdala and less in the cerebellum, which may help explain why motor function seems to be more compromised in rats than humans upon cannabinoid application.[12]

Spine[edit]

Many of the documented analgesic effects of cannabinoids are based on the interaction of these compounds with CB1 receptors on spinal cord interneurons in the superficial levels of the dorsal horn, known for its role in nociceptive processing. In particular, the CB1 is heavily expressed in layers 1 and 2 of the spinal cord dorsal horn and in lamina 10 by the central canal. Dorsal root ganglion also express these receptors, which target a variety of peripheral terminals involved in nociception. Signals on this track are also transmitted to the periaqueductal gray (PAG) of the midbrain. Endogenous cannabinoids are believed to exhibit an analgesic effect on these receptors by limiting both GABA and glutamate of PAG cells that relate to nociceptive input processing, a hypothesis consistent with the finding that ananadamide release in the PAG is increased in response to pain-triggering stimuli.[1]

Other[edit]

CB1 is expressed on several types of cell in pituitary gland, thyroid gland, and possibly in the adrenal gland.[5] CB1 is also expressed in several cells relating to metabolism, such as fat cells, muscle cells, liver cells (and also in the endothelial cells, Kupffer cells and stellate cells of the liver), and in the digestive tract.[5] These receptor also expressed in the lungs and the kidney.

CB1 is present on Leydig cells and human sperms. In females, it is present in the ovaries, oviducts myometrium, decidua, and placenta. It has also been implicated in the proper development of the embryo.[5]

Function[edit]

Health and disease[edit]

Several studies have implicated the CB1 receptor in the maintenance of homeostasis in health and disease. In a rodent neuropathic pain model, increased expression of these receptors was seen in thalamic neurons, the spinal cord, and dorsal root ganglion.[12] In addition, increased receptor expression has been found in human hepatocellular carcinoma tumor samples and other human prostate cancer cells. The expression of these receptors is believed to modulate neurotransmitter release in a manner that prevents the development of excessive neuronal activity, reducing pain and other inflammatory symptoms. This finding is consistent with the localization of CB1 receptors to the terminals of central and peripheral neurons, and the established mediation of both excitatory and inhibitory neurotransmitters acetylcholine, noradrenaline, dopamine, 5-HT, GABA, glutamate, D-aspartate, and cholecystokinin.[12] Through its primary action as a Gi coupled receptor, CB1 inhibits production of cyclic adenosine monophosphate (cAMP), metabotropically inhibiting all NT release.

Enhanced receptor expression following disease has been found to result in a leftward shift in the log dose-response curve of cannabinol, and also an increase in the size of its maximal effects.[12]

Anxiety response to novelty[edit]

A CB1 receptor knock-out mouse study examined the effect that these receptors play on exploratory behavior in novel situations. Researchers selectively targeted glutamatergic and GABAergic cortical interneurons and studied results in open field, novel object, and sociability tests. Eliminating glutamaterigic cannabinoid receptors led to decreased object exploration, social interactions, and increased aggressive behavior. In contrast, GABAergic cannabinoid receptor-knockout mice showed increased exploration of objects, socialization, and open field movement.[13] These opposing effects reveal the importance of the endocannabinoid system in regulating anxiety-dependent behavior. Glutamatergic CB1receptors not only are responsible for mediating aggression but produce anxiolytic-like function by inhibiting excessive arousal, which prevented the mice from exploring both animate and inanimate objects. In contrast, GABAergic CB1 receptors appear to control an anxiogenic-like function by limiting inhibitory transmitter release. Taken together, these results illustrate the regulatory function of the CB1 receptor on the organism's overall sense of arousal during novel situations and suggest that investigatory drive is associated with impulsive behavior.

Another study found that differential synthesis of anandamide and 2-AG in response to stress mediated beneficial effects of the hypothalamic-pituitary-adrenal axis. These effects were eliminated by the application of the CB1 antagonist AM251, illustrating that this receptor is essential for modulating the function of the stress response.[14]

Liver[edit]

In the liver, activation of the CB1 receptor is known to increase de novo lipogenesis,[15] Activation of presynaptic CB1 receptors is also known to inhibit sympathetic innervation of blood vessels and contributes to the suppression of the neurogenic vasopressor response in septic shock.[16]

Gastrointestinal activity[edit]

Inhibition of gastrointestinal activity has been observed after administration of THC or anandamide. This effect is assumed to be CB1-mediated, since this receptor is expressed by the peptide hormone cholecystokinin, and application of the CB1-specific antagonist SR 141716A (Rimonabant) blocks the effect. Another report, however, suggests that inhibition of intestinal motility may also have a CB2-mediated component.[17]

The CB1 receptor inverse agonist rimonabant has been found to reduce intake of food or sweet solutions in both humans and mice. Targeting this receptor with rimonabant has been found to prevent the THC-induced enhancement of DA release in the nucleus accumbens shell from food, suggesting that these receptors may be involved in determining the hedonic value of food.[18] In addition, CB1 inhibits ghrelin release, normally happening when the stomach is stretched. In the presence of a relatively active system, overeating is promoted. This is the genesis of its appetite-stimulating effects, colloquially called "the munchies"(source needed).

Cardiovascular activity[edit]

Cannabinoids are well known for their cardiovascular activity. Activation of peripheral CB1 receptors contributes to hemorrhagic and endotoxin-induced hypotension.[19] Anandamide and 2-AG, produced by macrophages and platelets, respectively, may mediate this effect.[19] A likely candidate for this function is the heterodimer of CB1 and adenosine 2a. Through an opposing mechanism of action (A2A elevates cAMP), together, they may serve to regulate cardiac blood supply, and thus output.

Pain[edit]

Anandamide attenuates the early phase or the late phase of pain behavior produced by formalin-induced chemical damage.[citation needed] This effect is produced by interaction with CB1 (or CB1-like) receptors, located on peripheral endings of sensory neurons involved in pain transmission. Palmitoylethanolamide, which like anandamide is present in the skin, also exhibits peripheral antinociceptive activity during the late phase of pain behavior. Palmitoylethanolamide, however, does not bind to either CB1 or CB2. Its analgesic activity is blocked by the specific CB2 antagonist SR144528, though not by the specific CB1 antagonist SR141716A. Hence, a CB2-like receptor was postulated.[citation needed]

Plasticity[edit]

A recent study compared the endocannabinoid induction of LTD and STD in the bed nucleus of the stria terminalis (BNST) and striatum. Results found that both short- and long-term effects were dependent on CB1 receptor activation in the striatum, whereas LTD induction in the BNST relied on TRPV1 receptor. Effects vary based on the endocannabinoid molecule: 2-AG was found to act on presynaptic CB1 receptors to mediate retrograde short-term depression following activation of L-type calcium currents, whereas anandamide was synthesized after mGluR5 activation and triggered autocrine signalling that induced long-term depression.[20] These findings demonstrate the CB1 receptor as a direct mechanism for the brain to selectively inhibit neuronal excitability over variable time scales. By selectively internalizing different receptors, the brain may limit the production of specific endocannabinoids to favor a time scale in accordance with its needs. mGlu5 forms a heterodimer with A2A, which allows endocannabinoids to regulate their own levels, as they inhibit cAMP production, thus increase free adenosine to agonise A2A. This forms a feedback loop between the positive and negative metabotropic receptors, which can maintain a relatively similar homeostasis with any neuron connected through an electrical synapse.

Drug and behavioral addictions[edit]

Several recent reviews on CB1 receptors and addiction have indicated that CB1 receptor activation reinstates drug seeking behavior in addicts.[21][22][23] In humans, this results from the influence that limbic CB1 receptors have on mesolimbic dopamine neurons, specifically dopamine receptors in the nucleus accumbens.[23] As a consequence, CB1 receptor antagonists reduce drug seeking behavior in addicts.[21][22][23]

Olfaction[edit]

The CB1 receptor is expressed by a number of neurons that project from the anterior olfactory nucleus to the ipsilateral main olfactory bulb. However, the effects of cannabinoids on synaptic activity in these neurons has not been well-studied and its effects on olfaction warrant further research in rodents.[24] Cannabinoids are not known to have effects on olfaction in humans. However, as with the rest of the brain, it plays a crucial role in modulation of NT release.

Use of antagonists[edit]

Selective CB1 agonists may be used to isolate the effects of the receptor from the CB2 receptor, as most cannabinoids and endocannabinoids bind to both receptor types.[1] CB1 selective antagonists are used for weight reduction and smoking cessation (see Rimonabant). A substantial number of antagonists of the CB1 receptor have been discovered and characterized. TM38837 has been developed as a CB1 receptor antagonist that is restricted to targeting only peripheral CB1 receptors.

Ligands[edit]

Agonists[edit]

Selective [edit]

Unspecified Efficacy [edit]

Inverse [edit]

Partial [edit]

Endogenous[edit]
Phyto/Synthetic[edit]

Full [edit]

Endogenous[edit]
Phyto/Synthetic[edit]

Antagonists [edit]

Binding affinities[edit]

CB1 affinity (Ki) Efficacy towards CB1 CB2 affinity (Ki) Efficacy towards CB2 Type References
Anandamide 78nM Full agonist 370nM  ? Endogenous
N-Arachidonoyl dopamine  ? Agonist  ?  ? Endogenous
2-Arachidonoylglycerol  ? Full agonist  ?  ? Endogenous
2-Arachidonyl glyceryl ether 21 nM Full agonist 480nM Full agonist Endogenous
Tetrahydrocannabinol 10nM Partial agonist 24nM Partial agonist Phytogenic [25] [26]
EGCG 33.6 μM Agonist >50μM  ? Phytogenic
AM-1221 52.3nM Agonist 0.28nM Agonist Synthetic [27]
AM-1235 1.5nM Agonist 20.4nM Agonist Synthetic [28]
AM-2232 0.28nM Agonist 1.48nM Agonist Synthetic [28]
UR-144 150 nM Full agonist 1.8 nM Full agonist Synthetic [29]
JWH-007 9.0nM Agonist 2.94nM Agonist Synthetic [30]
JWH-015 383nM Agonist 13.8nM Agonist Synthetic [30]
JWH-018 9.00 ± 5.00 nM Full agonist 2.94 ± 2.65 nM Full agonist Synthetic [31]

Evolution[edit]

The CNR1 gene is used in animals as a nuclear DNA phylogenetic marker.[10] This intronless gene has first been used to explore the phylogeny of the major groups of mammals,[32] and contributed to reveal that placental orders are distributed into four major clades: Xenarthra, Afrotheria, Laurasiatheria, Euarchonta, and Glires. CNR1 has also proven useful at lower taxonomic levels, such as rodents,[33][34] and for the identification of dermopterans as the closest primate relatives.[35]

See also[edit]

References[edit]

  1. ^ a b c d e f g h i j Elphick, M. R.; Egertova, M. (2001). "The neurobiology and evolution of cannabinoid signalling". Philosophical Transactions of the Royal Society B: Biological Sciences 356 (1407): 381–408. doi:10.1098/rstb.2000.0787. PMC 1088434. PMID 11316486.  edit
  2. ^ a b c d e Pertwee, R. G. (2006). "The pharmacology of cannabinoid receptors and their ligands: An overview". International Journal of Obesity 30: S13–S18. doi:10.1038/sj.ijo.0803272. PMID 16570099.  edit
  3. ^ a b c "Entrez Gene: CNR1 cannabinoid receptor 1 (brain)". 
  4. ^ Demuth, D.; Molleman, A. (2006). "Cannabinoid signalling". Life Sciences 78 (6): 549–563. doi:10.1016/j.lfs.2005.05.055. PMID 16109430.  edit
  5. ^ a b c d e Pagotto, U.; Marsicano, G.; Cota, D.; Lutz, B.; Pasquali, R. (2006). "The emerging role of the endocannabinoid system in endocrine regulation and energy balance". Endocrine Reviews 27 (1): 73–100. doi:10.1210/er.2005-0009. PMID 16306385.  edit
  6. ^ Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley P, Christopoulos A, Pertwee RG, Ross RA (November 2005). "Allosteric modulation of the cannabinoid CB1 receptor". Mol. Pharmacol. 68 (5): 1484–95. doi:10.1124/mol.105.016162. PMID 16113085. 
  7. ^ Navarro HA, Howard JL, Pollard GT, Carroll FI (April 2009). "Positive allosteric modulation of the human cannabinoid (CB1) receptor by RTI-371, a selective inhibitor of the dopamine transporter". Br. J. Pharmacol. 156 (7): 1178–84. doi:10.1111/j.1476-5381.2009.00124.x. PMC 2697692. PMID 19226282. 
  8. ^ Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, Reynet C, Wong Kai In P (November 2007). "PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats". Br. J. Pharmacol. 152 (5): 805–14. doi:10.1038/sj.bjp.0707347. PMC 2190018. PMID 17592509. 
  9. ^ Fan N, Yang H, Zhang J, Chen C (February 2010). "Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Δ9-THC exposure-impaired hippocampal synaptic plasticity". J. Neurochem. 112 (3): 691–702. doi:10.1111/j.1471-4159.2009.06489.x. PMC 2809144. PMID 19912468. 
  10. ^ a b "OrthoMaM phylogenetic marker: CNR1 coding sequence". 
  11. ^ Burns, H.; Van Laere, K.; Sanabria-Bohórquez, S.; Hamill, T.; Bormans, G.; Eng, W.; Gibson, R.; Ryan, C.; Connolly, B.; Patel, S.; Krause, S.; Vanko, A.; Van Hecken, A.; Dupont, P.; De Lepeleire, I.; Rothenberg, P.; Stoch, S. A.; Cote, J.; Hagmann, W. K.; Jewell, J. P.; Lin, L. S.; Liu, P.; Goulet, M. T.; Gottesdiener, K.; Wagner, J. A.; De Hoon, J.; Mortelmans, L.; Fong, T. M.; Hargreaves, R. J. (2007). "18FMK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor". Proceedings of the National Academy of Sciences of the United States of America 104 (23): 9800–9805. Bibcode:2007PNAS..104.9800B. doi:10.1073/pnas.0703472104. PMC 1877985. PMID 17535893.  edit
  12. ^ a b c d e Pertwee, R. G. (2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin". British Journal of Pharmacology 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.  edit
  13. ^ Häring, M.; Kaiser, N.; Monory, K.; Lutz, B. (2011). "Circuit Specific Functions of Cannabinoid CB1 Receptor in the Balance of Investigatory Drive and Exploration". In Burgess, Harold A. PLoS ONE 6 (11): e26617. doi:10.1371/journal.pone.0026617. PMC 3206034. PMID 22069458.  edit
  14. ^ Hill, M. N.; McLaughlin, R. J.; Bingham, B.; Shrestha, L.; Lee, T. T. Y.; Gray, J. M.; Hillard, C. J.; Gorzalka, B. B.; Viau, V. (2010). "Endogenous cannabinoid signaling is essential for stress adaptation". Proceedings of the National Academy of Sciences 107 (20): 9406–9411. doi:10.1073/pnas.0914661107. PMC 2889099. PMID 20439721.  edit
  15. ^ Osei-Hyiaman, D.; Depetrillo, M.; Pacher, P.; Liu, J.; Radaeva, S.; Bátkai, S.; Harvey-White, J.; MacKie, K.; Offertáler, L.; Wang, L.; Kunos, G. (2005). "Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity". The Journal of Clinical Investigation 115 (5): 1298–1305. doi:10.1172/JCI23057. PMC 1087161. PMID 15864349.  edit
  16. ^ Godlewski, G.; Malinowska, B.; Schlicker, E. (2004). "Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats". British Journal of Pharmacology 142 (4): 701–708. doi:10.1038/sj.bjp.0705839. PMC 1575049. PMID 15159284.  edit
  17. ^ Mathison, R.; Ho, W.; Pittman, Q.; Davison, J.; Sharkey, K. (2004). "Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats". British Journal of Pharmacology 142 (8): 1247–1254. doi:10.1038/sj.bjp.0705889. PMC 1575196. PMID 15249429.  edit
  18. ^ De Luca, M. A.; Solinas, M.; Bimpisidis, Z.; Goldberg, S. R.; Di Chiara, G. (2011). "Cannabinoid facilitation of behavioral and biochemical hedonic taste responses". Neuropharmacology 63 (1): 161–168. doi:10.1016/j.neuropharm.2011.10.018. PMC 3705914. PMID 22063718.  edit
  19. ^ a b Varga, K.; Wagner, J. A.; Bridgen, D. T.; Kunos, G. (1998). "Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension". The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 12 (11): 1035–1044. PMID 9707176.  edit
  20. ^ Puente, N.; Cui, Y.; Lassalle, O.; Lafourcade, M.; Georges, F. O.; Venance, L.; Grandes, P.; Manzoni, O. J. (2011). "Polymodal activation of the endocannabinoid system in the extended amygdala". Nature Neuroscience 14 (12): 1542–1547. doi:10.1038/nn.2974. PMID 22057189.  edit
  21. ^ a b De Vries TJ, Schoffelmeer AN (August 2005). "Cannabinoid CB1 receptors control conditioned drug seeking". Trends Pharmacol. Sci. 26 (8): 420–6. doi:10.1016/j.tips.2005.06.002. PMID 15992935. 
  22. ^ a b Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ (June 2008). "The role of CB1 receptors in psychostimulant addiction". Addict Biol 13 (2): 225–38. doi:10.1111/j.1369-1600.2008.00109.x. PMID 18482432. 
  23. ^ a b c Melis M, Pistis M (December 2012). "Hub and switches: endocannabinoid signalling in midbrain dopamine neurons". Philos. Trans. R. Soc. Lond., B, Biol. Sci. 367 (1607): 3276–85. doi:10.1098/rstb.2011.0383. PMC 3481525. PMID 23108546. 
  24. ^ Elphick, M. R.; Egertova, M. (2001). "The neurobiology and evolution of cannabinoid signalling". Philosophical Transactions of the Royal Society B: Biological Sciences 356 (1407): 381–408. doi:10.1098/rstb.2000.0787. PMC 1088434. PMID 11316486.  edit
  25. ^ "PDSP Database - UNC". Retrieved 11 June 2013. 
  26. ^ "PDSP Database - UNC". Retrieved 11 June 2013. 
  27. ^ WO patent 200128557, Makriyannis A, Deng H, "Cannabimimetic indole derivatives", granted 2001-06-07 
  28. ^ a b US patent 7241799, Makriyannis A, Deng H, "Cannabimimetic indole derivatives", granted 2007-07-10 
  29. ^ Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD (January 2010). "Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity". J. Med. Chem. 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781. 
  30. ^ a b Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, Showalter VM, Abood ME, Martin BR (August 2000). "Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2)receptor binding". Drug Alcohol Depend 60 (2): 133–40. doi:10.1016/S0376-8716(99)00152-0. PMID 10940540. 
  31. ^ Aung, M.M. et al. (2000). "Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding". Drug and Alcohol Dependence 60: 133–140. 
  32. ^ Murphy WJ, Eizirik E, Johnson WE, Zhang YP, Ryder OA, O'Brien SJ (February 2001). "Molecular phylogenetics and the origins of placental mammals". Nature 409 (6820): 614–8. doi:10.1038/35054550. PMID 11214319. 
  33. ^ Blanga-Kanfi S, Miranda H, Penn O, Pupko T, DeBry RW, Huchon D (2009). "Rodent phylogeny revised: analysis of six nuclear genes from all major rodent clades". BMC Evol. Biol. 9: 71. doi:10.1186/1471-2148-9-71. PMC 2674048. PMID 19341461. 
  34. ^ DeBry RW (October 2003). "Identifying conflicting signal in a multigene analysis reveals a highly resolved tree: the phylogeny of Rodentia (Mammalia)". Syst. Biol. 52 (5): 604–17. doi:10.1080/10635150390235403. PMID 14530129. 
  35. ^ Janecka JE, Miller W, Pringle TH, Wiens F, Zitzmann A, Helgen KM, Springer MS, Murphy WJ (November 2007). "Molecular and genomic data identify the closest living relative of primates". Science 318 (5851): 792–4. Bibcode:2007Sci...318..792J. doi:10.1126/science.1147555. PMID 17975064. 

External links[edit]

Further reading[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.